is the second most common chronic inflammatory disorder worldwide; however, a noninvasive means of accurately assessing the severity and extent of intestinal inflammation is currently not available. The aim of the present study was to develop a noninvasive imaging modality to detect and evaluate ileitis in SAMP1/YitFc (SAMP) mice. Methods: An image-enhancing ultrasound (US) contrast agent, consisting of encapsulated gaseous microbubbles (MB), was developed specifically to bind mucosal addressin cellular adhesion molecule-1 (MAdCAM-1), a mucosal-restricted addressin up-regulated during gut inflammation. MAdCAM-1-targeted MB (MB M ) were tested for binding specificity on MAdCAM-1 protein and tumor necrosis factor (TNF)-stimulated SVEC4-10 endothelial cells using an in vitro flow chamber assay and for their ability to detect and quantify ileitis by intravital microscopy and transabdominal US. Results: Under in vitro flow conditions, a 100-fold increase in MB M binding was observed on MAdCAM-1 protein compared with nonspecific MB (P < .001). TNF-stimulated endothelial cells bound significantly more MB M vs nonspecific MB (P < .001), which was abrogated after preincubation with antiMAdCAM-1 antibodies (P < .001). In vivo, MB M specifically accumulated in focal areas of ileal inflammation and produced stronger acoustic echoes, measured by average video intensity, in SAMP vs uninflamed AKR mice (P < .001) or SAMP given nonspecific MB (P < .001). MB M -specific video intensity showed a strong positive correlation with total ileal inflammatory scores (R 2 ‫؍‬ 0.92). Conclusions: We have developed a novel intravascular US contrast agent targeting MAdCAM-1 that specifically detects and quantifies intestinal inflammation in experimental ileitis, providing the potential for a reliable, noninvasive means to diagnose and monitor disease in patients with IBD.
Background & Aims: Inflammatory bowel disease (IBD)
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Conclusions:
We have developed a novel intravascular US contrast agent targeting MAdCAM-1 that specifically detects and quantifies intestinal inflammation in experimental ileitis, providing the potential for a reliable, noninvasive means to diagnose and monitor disease in patients with IBD.
T o date, endoscopy, barium contrast x-ray studies, computed tomography, and transabdominal ultrasound (US) are the most common procedures used by gastroenterologists to monitor patients with IBD. 1 Only endoscopy can confirm the presence of inflammation because it provides direct visual inspection of the bowel; however, it is limited to areas accessible to the endoscope and will only reveal inflammation when focal sites originating in deeper tissue layers have penetrated the lumen. The use of transabdominal US for the evaluation of Crohn's disease (CD) was implemented as early as 1979. 2 Technologic advances in high-frequency US have greatly improved resolution in recent years, and there are now several research groups actively investigating the application of transabdominal US for the management of IBD. [3] [4] [5] [6] [7] [8] Visible factors, such as loss of peristalsis, increased rigidity under pressure from the US probe, wall thickness changes, and disruption of the normal 5-layer architecture have been used to assess disease severity, but it remains uncertain whether these changes are due to inflammation, fibrosis, or a combination of both.
Image-enhancing US contrast agents have been under development for a number of years and are approved by the Food and Drug Administration (FDA) for use in cardiac imaging. Recently, a more direct approach for imaging active inflammation has been made possible by conjugating antibodies to specific endothelial cell adhe-sion molecules, expressed during an inflammatory process, to the external surface of lipid shell microbubbles (MB). 9 Of particular importance to IBD is the expression of mucosal addressin cellular adhesion molecule-1 (MAd-CAM-1), a tissue-specific endothelial cell adhesion molecule that is critical for lymphocyte homing to the gut. 10 Expression of MAdCAM-1 in the adult is restricted to mucosal tissues and has been shown to be dramatically up-regulated within focal sites of intestinal inflammation in both animal models of IBD [11] [12] [13] [14] [15] [16] [17] and in human tissue samples from patients with CD and ulcerative colitis (UC). 18 -20 We therefore hypothesized that development of an intravascular US contrast agent specifically targeted to MAdCAM-1 would augment existing imaging technologies and provide a means to detect and evaluate noninvasively active intestinal inflammation, such as that observed in IBD.
In the present study, targeted MB constructs were synthesized by conjugation of antibodies against MAd-CAM-1 to the external surface of lipid shell MB. Specific attachment and accumulation of MAdCAM-1-specific MB (MB M ) was verified using an in vitro flow chamber system that has the ability to simulate a range of physiologic shear flow rates of the intestinal microcirculation across tumor necrosis factor (TNF)-stimulated cultured endothelial monolayers known to express MAdCAM-1. 21 Finally, using the SAMP1/YitFc (SAMP) mouse strain, a model of Crohn's-like ileitis that spontaneously develops chronic intestinal inflammation by 20 weeks of age with 100% penetrance, 22, 23 in vivo localization of MB M was validated by intravital microscopy and contrast-enhanced transabdominal US. The severity and extent of disease in SAMP compared with uninflamed control AKR mice significantly correlated to the increased video intensity, determined by semiquantitative analysis, of the resulting US images. Therefore, we report herein the development of a novel intravascular US contrast agent specifically targeting MAdCAM-1 that can be effectively used to augment existing US-imaging technologies and that has the ability to detect and evaluate the severity of intestinal inflammation in vivo in an animal model of Crohn's ileitis. Furthermore, the targeted imaging strategy presented here lays the foundation to pursue similar technologies that have the potential to provide a cost-effective, noninvasive means to improve the diagnosis, clinical care, and management of patients with IBD.
Materials and Methods

Reagents
Antibodies. The HB-9478 (ATCC, Manassas, VA) and KLH/G2a-1-1 (Southern Biotechnology Associates, Birmingham, AL) clones were propagated to produce MECA-367 (antimurine MAdCAM-1) and isotype control rat IgG2a antibodies, respectively.clones were propagated to produce MECA-367 (antimurine MAdCAM-1) and isotype control rat IgG2a antibodies, respectively.
Preparation of targeted MB. Lipid shell MB were prepared by sonic dispersion of decafluorobutane gas in an aqueous medium containing phosphatidyl choline, polyethylene glycol (PEG) stearate, and biotin-PEG-distearoyl phosphatidylethanolamine (DSPE) as described previously. 24 The dialkylcarbocyanines, indocarbocyanine (DiI), or oxacarbocyanine (DiO) were incorporated into MB lipid shells for fluorescent detection and to distinguish simultaneously the MB M and isotype control MB (MB I ), respectively, as previously described. 24 Quantitation of biotinylated MB was determined (Coulter Multisizer IIe; Beckman Coulter, Hialeah, FL) and streptavidin (3 g/10 7 MB) (Sigma Chemical Co., St. Louis, MO) added for 30 minutes at 0°C. Biotinylated MECA-367 or isotype control antibody was subsequently added (7.5 g Ab/10 7 MB) for 30 minutes at 0°C. Antibody-coupled MB were used immediately or aliquoted, flash frozen in liquid nitrogen, and stored at Ϫ80°C until further use.
In Vitro Studies
Flow cytometry. Attachment of rat IgG2a antimouse MECA-367 antibodies to the external surface of lipidshelled MB was confirmed by flow cytometry (see Figure 1A ), following addition of Cy3-conjugated mouse anti-rat IgG antibodies ( Jackson Immuno Research Laboratories, West Grove, PA). Samples were evaluated with a FACSCaliber flow cytometer (Becton-Dickinson, Franklin Lakes, NJ), which demonstrated that addition of increasing concentrations of biotinylated MECA-367 (0.0, 0.075, 0.75, 7.5, 75, 750 g Ab/10 7 MB) resulted in increased incremental fluorescence intensity until saturation was reached near 7.5 g Ab/10 7 MB. All MB M preparations used in subsequent experiments were synthesized using this concentration.
Cell culture. The SVEC4-10 murine endothelial cell line (ATCC) was chosen for its ability to express MAdCAM-1 following TNF stimulation. 21, 25 Thirty-five-millimeter culture dishes (Corning, Corning, NY) were precoated with 5 g/cm 2 fibronectin (Roche, Indianapolis, IN) for 2 hours at room temperature. Cells were grown to confluency using highglucose Dulbecco's modified Eagle medium supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin (all from Gibco, Grand Island, NY), in 10% CO 2 atmosphere at 37°C and 98% humidity. Cells were cultured in the presence or absence of 20 ng/mL recombinant murine TNF (R&D Systems, Minneapolis, MN) for 24 hours and subsequently subjected to in vitro flow chamber assays.
Flow chamber binding assay. A commercially available Parallel Plate Flow Chamber (Glycotech, Rockville, MA) was used to modulate shear flow across recombinant MAdCAM-1 (rMAdCAM-1) substrate or cultured endothelial monolayers. A syringe pump (Harvard Appara-tus, Holliston, MA) was used to maintain a continuous shear stress of 0.5 dyne/cm 2 , and MB were infused at a concentration of 5 ϫ 10 5 MB/mL. Twenty optical fields were recorded onto an sVHS cassette through the use of a CCD camera (Matsushita Electric Industrial Co., Ltd, Secaucus, NJ). Fluorescent excitation of DiI was used to verify the presence of bound MB.
In Vivo Studies SAMP model of spontaneous ileitis. SAMP and control AKR/J (AKR, parental background strain) mouse colonies were maintained under specific pathogen-free conditions in a barrier facility, and all in vivo experimental protocols described below were approved by the Animal Care and Use Committee at the University of Virginia. SAMP mice develop spontaneous ileitis with 100% penetrance by 20 weeks of age, with progression of disease severity over time. 22, 23 SAMP and AKR mice utilized for all experiments were Ն20 weeks of age.
Immunohistochemistry. Mice were killed 15 minutes after MECA-367 or isotype control antibody administration (50 g, intraperitoneally [IP]), and ileal tissues were removed, embedded in OCT (Sakura Finetek, Torrance, CA), and frozen in liquid nitrogen. Frozen tissues were then sectioned (10 m), incubated with biotinylated secondary antibody (anti-rat IgG, Vector Laboratories, Burlingame, CA), and incubated with an avidin/biotin complex; immunoreactive cells were visualized by addition of diaminobenzidine (DAB) substrate (both from VECTASTAIN Elite ABC kit, Vector Laboratories) and counterstained in hematoxylin.
Intravital microscopy. Mice were anesthetized with a solution (12.5 L/g, IP) containing ketamine hydrochloride (10 mg/mL), xylazine (1 mg/mL), and atropine (0.02 mg/mL). A small segment of bowel was exteriorized through an incision made along the linea alba, and Peyer's patches were identified by visual inspection and aligned on the optical pedestal of a custom-crafted plexiglass microscope stage. Ileal preparations were viewed under fluorescence microscopy (Carl Zeiss Inc., New York, NY), and optical filters (Carl Zeiss Inc.) were used to distinguish between DiI-labeled MB M and DiO-labeled MB I that were simultaneously administered via jugular vein cannulation (5 ϫ 10 6 of each MB in 200 L phosphatebuffered saline [PBS] ).
In vivo targeted US imaging. Mice were anesthetized as described above. MB (5 ϫ 10 6 in 200 L PBS) were delivered by jugular vein cannulation and mice imaged with an ATL HDI5000cv US machine (Philips Medical Systems, Best, The Netherlands) using an L7-4 transducer operating in pulse inversion mode with a mechanical index of 0.8. A pulsing interval of 10 seconds was then used to obtain the background signal from freely circulating MB. Tissue samples from regions of interest were obtained by US-guided placement of a 23-gauge needle inserted into the abdominal cavity. Mice were killed and ileal tissues harvested for histologic evaluation by a gastrointestinal (GI) pathologist blinded to the specimens, using an established scoring system and reported as total inflammatory score, as previously described. 23 All captured US images were recorded on sVHS (Matsushita Electric Industrial Co.) and transferred to digital format (Adobe Premier, Adobe Systems Incorporated, San Jose, CA) for off-line processing and analysis. Video intensity (VI) was calculated from US images with an in-house computer algorithm that subtracts a 4-frame average circulating background signal from the initial contrast-enhanced frame and color codes the image according to gray-scale VI, as previously described. 9 
Statistical Analysis
Significance levels for comparisons were obtained through the use of a 1-tailed Student t test for samples with unequal variance.
Results
Functional Evaluation of MAdCAM-1-Targeted Image Enhancing US Contrast Agents
The average mean MB diameter following antibody conjugation was shown to be 3.9 m (approximate size of a red blood cell), implying that the synthesized MB M construct was small enough to navigate through the pulmonary and renal circulations en route to its target protein. To test the specificity of MB M for MAdCAM-1, a saturating protein concentration of rMAdCAM-1 substrate was established using biotinylated MECA-367 and Europeum-labeled streptavidin. Increasing plated protein concentrations resulted in incremental increases in Europeum emission until a saturation concentration of just over 250 ng/mL was reached ( Figure 1C ). Under flow conditions of 0.5 dyne/cm 2 (lower limits of shear rates found in the intestinal microcirculation), interaction of MB M with rMAdCAM-1 substrate resulted in a 100-fold increase in the number of bound MB M /mm 2 relative to MB I (P Ͻ .001), and application of a blocking antibody against MAdCAM-1 significantly abrogated this binding (P Ͻ .001) ( Figure 1D ).
MB M Specificity and Binding Are Increased on Cultured Endothelial Cells Expressing MAdCAM-1 Under In Vitro Flow Conditions
Surface expression of MAdCAM-1 on cultured SVEC4-10 endothelial monolayers was confirmed by immunocytochemistry. Unstimulated cells showed minimal constitutive expression of MAdCAM-1 (Figure 2A) , which dramatically increased following TNF stimulation (20 ng/mL, 24 hours); staining using an isotype control antibody resulted in minimal immunoreactivity on TNF-stimulated cells ( Figure 2C ). To test the specificity of MB M binding on MAdCAM-1 expressing endothelial cells, we performed an in vitro flow chamber functional binding assay on TNF-stimulated SVEC4-10 cells. Minimum binding was observed following infusion of DiI labeled MB M across unstimulated endothelial cells (Figure 2D and 2E) , whereas binding was greatly enhanced after stimulation with TNF ( Figure 2G ). These differences, although not apparent under bright-field microscopy, were clearly evident under fluorescence microscopy ( Figure 2D-G) . Quantitative analysis of the specific attachment and accumulation of infused MB M on cultured endothelial cells is summarized in Figure 2H . TNFstimulated SVEC4-10 cells bound significantly more MB M ( Figure 2H , inset) compared with unstimulated cells, whereas preincubation of a blocking anti-MAd-CAM-1 antibody prior to infusion significantly reduced the number of adherent MB M (484 Ϯ 50 vs 75 Ϯ 19 and 29 Ϯ 8 MB M /mm 2 , respectively; P Ͻ .001). MB M specificity was further supported because nonspecific MB I binding was significantly reduced on both unstimulated and TNF-stimulated SVEC4-10 cells (26 Ϯ 3 and 11 Ϯ 2 MB I /mm 2 , respectively; P Ͻ .001 vs MB M binding on stimulated cells).
MB M Contrast-Enhanced Transabdominal US Detects and Correlates With the Severity of Ileal Inflammation in SAMP Mice
Immunohistochemical analysis of healthy AKR control mice showed faint basal expression of MAd-CAM-1 in the terminal ileum ( Figure 3A) , whereas age-matched diseased SAMP (Ն20 weeks) showed strong immunoreactivity for MAdCAM-1 on vessels morphologically consistent with venules of the lamina propria within focal areas of inflammation ( Figure 3B ). Isotype control antibodies showed no reactivity and confirmed specificity of MAdCAM-1 expression and up-regulation in the inflamed ileum of SAMP mice ( Figure 3C ). In addition, a second anti-MAdCAM-1 antibody (MECA-89) provided identical immunolocalization of MAd- CAM-1, which was abrogated following preincubation with murine rMAdCAM-1 protein (data not shown). To validate specificity of MB M on MAdCAM-1 expressing endothelial cells, intravital microscopy on preparations of SAMP Peyer's patches was performed to observe directly in vivo MB-endothelial cell interactions. MB M and MB I were fluorescently labeled with DiI and DiO, respectively, with peak emission spectrums centered around 565 and 500 nm, respectively. Following simultaneous infusion of MB M and MB I (5 ϫ 10 6 of each MB), optical filters distinguishing DiI-labeled MB M and DiO-labeled MB I showed increased accumulations of MB M throughout the microvasculature, whereas MB I showed little to no adherence on the same microvasculature ( Figure 3D and 3E).
Transabdominal US was then performed on experimental mice (Ն20 weeks of age) following intravascular delivery of MB constructs. US-guided placement of 23-gauge needles inserted into the abdominal cavity and aimed at strong acoustic echoes, appearing as bright regions during US imaging, corresponded to areas of macroscopically involved small intestine as well as enlarged, draining mesenteric lymph nodes upon necropsy of SAMP mice receiving MB M (Figure 4) . When comparing uninflamed control mice to diseased SAMP, healthy AKR mice generated weak background signals following either MB I or MB M infusion ( Figure 5A and 5B). Conversely, in SAMP mice, accumulations of MB M produced strong acoustic echoes, demonstrated in colorcoded US images ( Figure 5E ), compared with MB I that produced little baseline signal ( Figure 5D ). In addition, small intestinal tissues obtained under US-guided placement of 23-gauge needles ( Figure 5B and 5E, green box) localized to areas of inflamed ileal segments in SAMP mice showing severe villous blunting and infiltration of acute and chronic inflammatory cells ( Figure 5F ), whereas corresponding areas in AKR mice showed morphologically normal intestine with no inflammation, as determined by histologic evaluation. To quantify the signal strength of acoustic echoes received by the US transducer, background subtracted color-coded images were analyzed, and it was determined that VI of images obtained from SAMP mice infused with MB M were, on average, 900% stronger than images obtained from AKR control mice (P Ͻ .001); MB M consistently produced stronger acoustic echoes (increased VI) than MB I in SAMP mice (P Ͻ .001), whereas normal AKR mice showed weak acoustic signal strength and no significant difference in VI with either MB M or MB I ( Figure 6A ). Finally, VI of MB M contrast-enhanced in vivo and ex vivo US images showed a strong positive correlation (R 2 ϭ 0.92 and 0.93, respectively) with the severity of ileitis, evaluated as total inflammatory scores, in SAMP mice ( Figure 6B and 6C ).
Discussion
The use of transabdominal US for the evaluation of CD was implemented as early as 1979 wherein wall thickening of the terminal ileum and cecum, with accompanying inflammatory changes in the mesentery, yielded recognizable patterns in both longitudinal and transverse images. 2 These initial US images lacked sufficient resolution to provide a sensitive measure of disease activity, but technologic advances in high-frequency US have greatly improved resolution over the past 20 years, and there is now renewed interest in the application of US for the management of IBD. However, the use of wall thickness measurements to evaluate active intestinal inflammation, although reportedly successful in most investigations, remains a controversial issue. From the 440 patients examined by Limberg and Osswald, mean wall thickness of normal bowel was established to be 3.0 Ϯ 0.7 mm. 4 This is consistent with the results reported by Hata et al, who established the mean overall wall thickness in normal patients to be 2.8 mm, with no normal specimens exceeding 4.0 mm. 26 These results imply that a significant portion of normal individuals would be classified as abnormal, or regions of mild to moderate inflammation would go undetected, if a strict demarcation between diseased and normal bowel is based purely on wall thickness measurements. The targeted US contrast agent developed in this study would resolve these discrepancies and render transabdominal US a powerful diagnostic tool for the management of patients with both UC and CD.
The concept of using gaseous particles to enhance US imaging was first introduced in 1968, 27 and 16 years after these initial studies, a technique for producing encapsulated MB with sizes on the order of red blood cells was produced. 28 The first generation of stable albumin-shelled MB was developed at the University of Virginia in 1987, 29 and injections in which the mean MB size was less than 6 m successfully opacified the left ventricle in 82% of the studies, providing proof of the first peripherally injected US contrast agent durable enough to survive passage through the heart and small enough to traverse the pulmonary capillary network. 30 Subsequently, a human albumin MB encapsulating a uniquely fluorinated gas that has a low solubility in both blood and water was developed by Molecular Biosystems (San Diego, CA) and marketed under the trade name Optison. The octafluoropropane formulation extends the temporal window of the contrast agent to more than 5 minutes, allowing enough time to traverse the entire peripheral circulation. Optison received approval by the FDA for marketing in the United States on January 5, 1998, and from the European Commission in May of that year.
Over the past several years, members of our research group have been actively developing US contrast agents similar to Optison that are specific for inflammation. Contrast-enhanced renal US images of mice undergoing ischemia-reperfusion injury have shown that a more direct method of imaging active inflammation was possible by conjugating ligands to specific endothelial cell adhesion molecules to the external surface of the lipid-shell MB. 9 In the present study, we successfully conjugated rat anti-mouse antibodies detecting MAdCAM-1 to the external surface of lipid-shelled MB to produce a targeted contrast agent for use with transabdominal US to detect experimental ileitis. The mean MB diameter following antibody conjugation was shown to be 3.9 m (the approximate size of a red blood cell), implying that the targeted MB M construct was small enough to navigate through the pulmonary and renal circulations en route to its target protein. The present imaging strategy can be used as a research tool to further our current understanding into the pathogenesis and progression of IBD by monitoring in vivo mucosal inflammation in whole animals with colitis.
In addition, transabdominal US images obtained in the present study were acquired 5 minutes following injection of the targeted MB constructs. Postprocessing was made simple by a computational algorithm that automatically subtracted background signal from freely circulating MB to produce rapidly the color-coded images with a quantifiable measure of signal intensity. In practice, physicians could obtain a background-subtracted color-coded image of the bowel, complete with a digital measure of signal intensity, within a half hour and could do so repeatedly without imposing any significant health risk or undue discomfort on the patient.
In summary, with the current observation of a dramatic increase in the number of newly diagnosed cases of IBD in nearly all parts of the world, there exists a strong demand for a simple, inexpensive, and noninvasive procedure that will enable the gastroenterologist to assess routinely the degree and extent of active intestinal inflammation in patients with IBD. Here, we provide strong evidence that this can be potentially accomplished through the use of tissue-specific contrast imaging that extends the capabilities of existing US technologies by exploiting the natural mechanisms employed by lymphocytes for organ-specific migration.
